After excluding any patients with co-mutations in EGFR, ALK, and ROS1, there were 22 NSCLC patients with only BRAF mutation and 35 NSCLC patients with wild-type BRAF, and their demographic and clinic characteristics are shown in Table 1. This evidence concerns the gene ALK and non-small cell lung carcinoma.